Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Exploring the Association Between Plasma GFAP Level and Agitation Severity in Patients with Moderate to Severe Alzheimer’s Disease

FY 2024-25

Summary
Alzheimer disease (AD) is a growing challenge among older adults with Canada aging population. In addition to memory loss, some behavioural symptoms are especially challenging. Agitation is a common symptom in patients with AD, and makes the disease harder to manage for patients and caregivers as it can decrease their quality of life and is linked to higher death rates, earlier transfer to long-term care homes, and greater healthcare costs. However, safe treatment is lacking as current approved medications (brexpiprazole and risperidone) increase mortality risks for older adults. Previous research suggests that astrocytes, a major type of brain cell, may contribute to behavioural symptoms like agitation in AD when become reactive. Reactive astrocytes release toxic chemicals and cause inflammation in the brain. Glial fibrillary acid proteins (GFAP) levels in blood have been identified as a good measurement of reactive astrocytes in the brain, and has been investigated with general behavioural symptoms in AD. However, the relationship between blood GFAP levels and agitation severity in AD has not been investigated before.I propose that higher blood GFAP levels will be associated with agitation severity in AD. In this research, we will recruit patients with AD and agitation. Agitation severity will be measured with questionnaires with the primary caregiver; GFAP levels will be measured in patient blood samples. If the association between blood GFAP level and agitation severity is positive, our understanding of agitation underlying cause can be improved. With that, new, safer, and more effective medications can be developed. This may improve patients' quality of life, decrease the need for long-term care homes, and ease the financial burden on healthcare systems.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530281
Name
Pan Tiffany
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the Association Between Plasma GFAP Level and Agitation Severity in Patients with Moderate to Severe Alzheimer’s Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Agitation; Alzheimer'S Disease; Astrogliosis; Blood Biomarkers; Gfap; Neuroinflammation
Abstract
Alzheimer disease (AD) is a growing challenge among older adults with Canada aging population. In addition to memory loss, some behavioural symptoms are especially challenging. Agitation is a common symptom in patients with AD, and makes the disease harder to manage for patients and caregivers as it can decrease their quality of life and is linked to higher death rates, earlier transfer to long-term care homes, and greater healthcare costs. However, safe treatment is lacking as current approved medications (brexpiprazole and risperidone) increase mortality risks for older adults. Previous research suggests that astrocytes, a major type of brain cell, may contribute to behavioural symptoms like agitation in AD when become reactive. Reactive astrocytes release toxic chemicals and cause inflammation in the brain. Glial fibrillary acid proteins (GFAP) levels in blood have been identified as a good measurement of reactive astrocytes in the brain, and has been investigated with general behavioural symptoms in AD. However, the relationship between blood GFAP levels and agitation severity in AD has not been investigated before.I propose that higher blood GFAP levels will be associated with agitation severity in AD. In this research, we will recruit patients with AD and agitation. Agitation severity will be measured with questionnaires with the primary caregiver; GFAP levels will be measured in patient blood samples. If the association between blood GFAP level and agitation severity is positive, our understanding of agitation underlying cause can be improved. With that, new, safer, and more effective medications can be developed. This may improve patients' quality of life, decrease the need for long-term care homes, and ease the financial burden on healthcare systems.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pan, Tiffany
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~